Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: This patient presents with...

Question asked:

Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: This patient presents with high-risk, biochemically recurrent prostate cancer (Gleason 4+5=9, pT3bN1) with 18 years of treatment history and current PSA fluctuations on adaptive androgen deprivation therapy (ADT). Given the aggressive pathology, nodal involvement, and long treatment duration with multiple lines of hormonal therapy, we recommend intensified systemic therapy with next-generation hormonal agents plus consideration of PSMA-targeted radioligand therapy, guided by recent PSMA-PET imaging results. Recommendation: We recommend: (1) Repeat PSMA-PET imaging to definitively assess PSMA-avidity and metastatic burden; (2) If PSMA-positive and castration-resistant, prioritize Lu-177-PSMA radioligand therapy given prior extensive hormonal therapy; (3) If PSMA-negative or unavailable, initiate combination ADT with abiraterone or enzalutamide (whichever not previously used) with consideration of docetaxel based on disease tempo and performance status; (4) Evaluate eligibility for clinical trials targeting KMT2D-mutant or DNA repair-deficient prostate cancer. Multidisciplinary tumor board review with nuclear medicine and medical oncology is essential given the complex treatment history and need for optimal sequencing. Tumor Board: Cutting Edge: This 18-year veteran of prostate cancer with T3bN0MX disease, Gleason 4+5=9, and documented KMT2D mutations represents a castration-resistant scenario requiring novel precision approaches beyond standard ADT cycling. The PSA fluctuations (undetectable to >100) over nearly two decades, combined with adaptive therapy tolerance, suggest clonal heterogeneity and treatment-emergent resistance mechanisms that warrant molecular interrogation and consideration of emerging targeted/immunotherapy combinations. Recommendation: Immediately obtain comprehensive genomic profiling (tissue + liquid biopsy with ctDNA analysis) to identify actionable alterations beyond KMT2D, assess HRR pathway mutations (BRCA1/2, ATM, PALB2) for PARP inhibitor eligibility, and evaluate AR-V7 status. Based on PSMA-PET findings and prior SBRT, prioritize 177Lu-PSMA-617 radioligand therapy if PSMA-avid disease confirmed, or enroll in combination immunotherapy trials if immune biomarkers (TMB, MSI, PD-L1) are favorable—this patient's treatment duration and adaptive therapy history make him an ideal candidate for precision medicine approaches targeting resistance mechanisms rather than further hormonal manipulation alone. Tumor Board: Whole Person: For this patient with 18 years of advanced prostate cancer (T3bN0MX, Gleason 4+3 to 4+5, node-positive disease) who has exhausted multiple lines of therapy including surgery, radiation, ADT, and experimental vaccines, the supportive care focus should be on optimizing quality of life during adaptive therapy cycles while managing treatment-related side effects. The fluctuating PSA pattern (from <0.1 to >100) suggests the patient is using intermittent hormone therapy, which creates unique supportive care opportunities during both on-treatment and off-treatment periods. Recommendation: Implement a comprehensive supportive care program including: (1) supervised resistance training 3x/week to preserve muscle mass and bone health during ADT cycles, (2) high-protein nutrition plan (1.4g/kg/day) with vitamin D monitoring, (3) structured aerobic exercise during off-treatment periods to maximize recovery, and (4) pharmacologic management of hot flashes if impacting quality of life. During PSA rise periods, focus on stress reduction techniques (MBSR) and proactive symptom management to optimize treatment tolerance for potential future therapies. Synthesize these perspectives. Respond in this exact JSON format: { "synthesis": "A 2-3 sentence synthesis of the key takeaways for the patient", "consensus": ["Point where all three agree", "Another point of agreement"], "divergence": ["Point where they disagree", "Another area of disagreement"] } Focus on actionable insights for the patient's next doctor conversation.